Chinese venture firm GP Healthcare Capital has led a US$55 million series C financing round in MicuRx Pharmaceuticals, Inc., a bio-pharmaceutical company developing antibiotics to improve the treatment of resistant bacterial infections with operations in Shanghai and California. New investors GP TMT Capital, 3E Bioventures Capital and Delian Capital also participated in the round. Yu […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.